Condition (MeSH)
Tooth Loss
ClinicalTrials.gov lists 155 trials for Tooth Loss or a narrower condition beneath it. Institut Straumann AG has the most among industry and government lead sponsors, with 6.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
155 of the 155 trials are tagged with Tooth Loss itself; the rest are tagged with a narrower condition beneath it.
When did Tooth Loss trials start? (24)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 22
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 18 |
| 2025 | 22 |
| 2024 | 17 |
| 2023 | 10 |
| 2022 | 8 |
| 2021 | 5 |
| 2020 | 14 |
| 2019 | 7 |
| 2018 | 9 |
| 2017 | 5 |
Showing 10 of 24 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 19 trials starting in 2026 and about 20 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 11 trials still running at the 2026-10-09 snapshot; registered median of 20 months across 78 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Tooth Loss trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 1 |
| Phase 2 | 1 |
| Phase 2/3 | 2 |
| Phase 3 | 1 |
| Phase 4 | 7 |
| Not applicable | 104 |
| Observational | 39 |
How many Tooth Loss trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 12 |
| Recruiting | 25 |
| Enrolling by invitation | 4 |
| Active, not recruiting | 8 |
| Completed | 70 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Tooth Loss trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Institut Straumann AG | 6 |
| CeraRoot SL | 2 |
| McGuire Institute | 2 |
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Xenogeneic Bone Graft | 1 |
| Group A - test:Tooth extraction and intake of NSAID and a non-NSAID | 1 |
| Enamel Matrix Derivative (Emdogain) | 1 |
| Freeze Dried Bone Allograft | 1 |
| Alveolar Ridge Reconstruction | 1 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Tooth Loss trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Aortic valve replacement | 1 | 1 |
| Bacterial Pneumonia | 1 | 1 |
| Birth of a boy | 1 | 1 |
| Calcaneal spur | 1 | 1 |
| Chest Pains | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Tooth Loss? (201)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| The influence of guide stabilizers and their application sequences on trueness and precision of surgical guides in free end situations: An in vitro analysis. | Clinical oral implants research | 2024 | Yes |
| Effectiveness of traditional band and loop space maintainer vs 3D-printed space maintainer following the loss of primary teeth: a randomized clinical trial. | Scientific reports | 2024 | Yes |
| Tooth Loss and Caries Experience of Elderly Chileans in the Context of the COVID-19 Pandemic in Five Regions of Chile. | International journal of environmental research and public health | 2023 | Yes |
| Tooth-level predictors of tooth loss and exposed bone after radiation therapy for head and neck cancer. | Journal of the American Dental Association (1939) | 2023 | Yes |
| Type 1 diabetes and oral health: Findings from the Epidemiology of Diabetes Interventions and Complications (EDIC) study. | Journal of diabetes and its complications | 2022 | Yes |
Showing 5 of 201 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.